Bindong Liu to Disease Progression
This is a "connection" page, showing publications Bindong Liu has written about Disease Progression.
Connection Strength
0.867
-
Liu J, Ma KL, Gao M, Wang CX, Ni J, Zhang Y, Zhang XL, Liu H, Wang YL, Liu BC. Inflammation disrupts the LDL receptor pathway and accelerates the progression of vascular calcification in ESRD patients. PLoS One. 2012; 7(10):e47217.
Score: 0.359
-
Feng Y, Sun Z, Fu J, Zhong F, Zhang W, Wei C, Chen A, Liu BC, He JC, Lee K. Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury. Kidney Int. 2024 Jul; 106(1):50-66.
Score: 0.199
-
Wei Q, Liu H, Tu Y, Tang RN, Wang YL, Pan MM, Liu BC. The characteristics and mortality risk factors for acute kidney injury in different age groups in China-a cross sectional study. Ren Fail. 2016 Oct; 38(9):1413-1417.
Score: 0.118
-
Liu J, Ma KL, Zhang Y, Wu Y, Hu ZB, Lv LL, Tang RN, Liu H, Ruan XZ, Liu BC. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease. Int J Biochem Cell Biol. 2015 Apr; 61:8-19.
Score: 0.105
-
Zheng M, Lv LL, Cao YH, Zhang JD, Wu M, Ma KL, Phillips AO, Liu BC. Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy. Clin Endocrinol (Oxf). 2012 May; 76(5):657-64.
Score: 0.087